Introduction/Background To evaluate the role of FloSeal for preventing symptomatic lymphocele following pelvic and/or para-aortic lymphadenectomy in patients with gynecological cancers.

Methodology Between Oct 2014 and Apr 2015, 40 patients with gynecological cancers planned for surgical management were randomly placed into FloSeal and non-FloSeal groups in a 1:1 ratio. Lymphocele incidence was evaluated using intravenous contrast-enhanced, abdominopelvic computed tomography 3–6 months after surgery. The quality of life questionnaire was completed by patients at 1, 3, and 6 months after surgery. The incidence of symptomatic lymphocele was compared using a chi-square test.

Results All patients underwent bilateral pelvic lymph node dissection, and eight patients in each group (40% vs. 44.4%, P > 0.999) underwent para-aortic lymph node dissection. The mean number of total, right pelvic, left pelvic, and para-aortic lymph nodes retrieved was similar between the groups. One patient (1/20, 5%) in the FloSeal group and three (3/18, 16.7%) in the non-FloSeal group developed lymphoceles (P = 0.328). The incidence of symptomatic lymphocele was 0% and 11% (2/18) in the FloSeal and non-FloSeal groups (P = 0.218), respectively. The mean time interval to drain removal (4.8 ± 2.0 days vs. 5.3 ± 2.2 days, P = 0.400) was shorter and the mean drain volume (1656 ± 1362 mL vs. 2022 ± 2301 mL, P = 0.550) was smaller in FloSeal group.

Conclusion The use of FloSeal after pelvic and/or para-aortic lymphadenectomy in patients with gynecological cancers is effective for preventing symptomatic lymphocele.

Disclosures This study was partly supported by the Baxter Healthcare, but it was not involved in the study design, in the collection, analysis and interpretation of data, in the writing of the manuscript, and in the decision to submit the manuscript for publication.